Downs Christopher's Insider Trades & SAST Disclosures
Downs Christopher's most recent trade in Cns Pharmaceuticals Inc was a trade of 40,000 Restricted Stock Units done . Disclosure was reported to the exchange on April 8, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Downs Christopher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 40,000 | 241 | - | - | Restricted Stock Units | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Apr 2024 | 40,000 | 201 | - | - | Option to purchase common stock | |
|
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 01 Feb 2024 | 66,666 | 103,438 (0%) | 0% | 0.3 | 20,000 | Common stock |
|
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 66,666 | 94,906 | - | - | Series A Warrant to purchase common stock | |
|
Cns Pharmaceuticals Inc
|
Downs Christopher | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 66,666 | 161,572 | - | - | Series B Warrant to purchase common stock | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.27 per share. | 22 Aug 2023 | 27,000 | 36,772 (0%) | 0% | 1.3 | 34,177 | Common Stock |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 521 | 9,772 (0%) | 0% | - | Common Stock | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 521 | 28,248 | - | - | Restricted Stock Units | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 17 Apr 2023 | 3,100 | 9,251 (0%) | 0% | 3.2 | 9,920 | Common Stock |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 6,067 | 28,768 | - | - | Restricted Stock Units | |
|
EBET Inc
|
Christopher Downs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 6,300 | 6,300 | - | - | Common Stock | |
|
EBET Inc
|
Christopher Downs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 6,300 | 75,000 | - | - | Restricted Stock Units | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 250,000 | 681,000 | - | - | Restricted Stock Units | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.31 per share. | 11 Mar 2022 | 33,000 | 184,500 (1%) | 0% | 0.3 | 10,230 | Common Stock |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.94 per share. | 06 Dec 2021 | 5,000 | 151,500 (0%) | 0% | 0.9 | 4,702 | Common Stock |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 19 Nov 2021 | 4,500 | 146,500 (0%) | 0% | 1.2 | 5,192 | Common Stock |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 131,000 | 431,000 | - | - | Option to purchase common stock (right to buy) | |
|
Cns Pharmaceuticals Inc
|
Christopher Downs | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 24 Aug 2020 | 142,000 | 142,000 (0%) | 0% | 2.0 | 289,680 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges